<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pyrazinamide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00339</strong>&#160; (APRD01206)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A pyrazine that is used therapeutically as an antitubercular agent.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00339/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00339/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00339.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00339.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00339.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00339.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00339.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00339">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-carbamylpyrazine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-pyrazinecarboxamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aldinamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pirazinamida</td><td>Spanish</td><td>INN</td></tr><tr><td>Pirazinamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>Pyrazinamid</td><td>German</td><td>INN</td></tr><tr><td>Pyrazinamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCF, JAN, BAN, BP 2011, JP XV, Ph. Eur. 7, Ph. Int. 4, USP 34</td></tr><tr><td>Pyrazinamidum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Ph. Eur. 7, Ph. Int. 4</td></tr><tr><td>Pyrazine carboxamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>pyrazine-2-carboxamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>Pyrazineamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pyrazinecarboxamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Pyrazinoic acid amide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Pyrizinamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Piraldina</td><td>Bracco</td></tr><tr><td>Prazina</td><td>Armoxindo</td></tr><tr><td>Pyrafat</td><td>Riemser</td></tr><tr><td>Pyrazide</td><td>Sanofi-Aventis</td></tr><tr><td>Tebrazid</td><td>Valeant</td></tr><tr><td>Tisamid</td><td>Orion</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Rifater</td><td>Isoniazid + Pyrazinamide + Rifampin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antitubercular-agents">Antitubercular Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>98-96-4</td></tr><tr><th>Weight</th><td>Average: 123.1127<br>Monoisotopic: 123.043261797</td></tr><tr><th>Chemical Formula</th><td>C<sub>5</sub>H<sub>5</sub>N<sub>3</sub>O</td></tr><tr><th>InChI Key</th><td>IPEHBUMCGVEMRF-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">pyrazine-2-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC(=O)C1=NC=CN=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00339.gif?1265922774">show</a>(8.68 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrazines</td></tr><tr><th>Direct parent</th><td>Pyrazinecarboxamides</td></tr><tr><th>Alternative parents</th><td>Primary Carboxylic Acid Amides; Polyamines; Enolates; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>carboxamide group; primary carboxylic acid amide; carboxylic acid derivative; polyamine; enolate; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrazinecarboxamides. These are compounds containing a pyrazine ring which bears a carboxamide.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.</td></tr><tr><th>Pharmacodynamics</th><td>Pyrazinamide kills or stops the growth of certain bacteria that cause tuberculosis (TB). It is used with other drugs to treat tuberculosis. It is a highly specific agent and is active only against <i>Mycobacterium tuberculosis</i>. In vitro and in vivo, the drug is active only at a slightly acid pH. Pyrazinamie gets activated to Pyrazinoic acid in the bacilli where it interferes with fatty acid synthase FAS I. This interferes with the bacteriums ability to synthesize new fatty acids, required for growth and replication.</td></tr><tr><th>Mechanism of action</th><td>Pyrazinamide diffuses into M. tuberculosis, where the enzyme pyrazinamidase converts pyrazinamide to the active form pyrazinoic acid. Under acidic conditions, the pyrazinoic acid that slowly leaks out converts to the protonated conjugate acid, which is thought to diffuse easily back into the bacilli and accumulate. The net effect is that more pyrazinoic acid accumulates inside the bacillus at acid pH than at neutral pH.
Pyrazinoic acid was thought to inhibit the enzyme fatty acid synthase (FAS) I, which is required by the bacterium to synthesise fatty acids. However, this theory was thought to have been discounted (PMID: 11914348). However, further studies reproduced the results of FAS I inhibition as the putative mechanism first in whole cell assay of replicating M. tuberculosis bacilli which have shown that pyrazinoic acid and its ester inhibit the synthesis of fatty acids (PMID: 17101678). This study was followed by in vitro assay of tuberculous FAS I enzyme that tested the activity with pyrazinamide, pyrazinoic acid and several classes of pyrazinamide analogs. Pyrazinamide and its analogs inhibited the activity of purified FAS I (PMID: 17485499). 

It has also been suggested that the accumulation of pyrazinoic acid disrupts membrane potential and interferes with energy production, necessary for survival of M. tuberculosis at an acidic site of infection. 

Pyrazinoic acid has also been shown to bind to the ribosomal protein S1 (RpsA) and inhibit trans-translation. This may explain the ability of the drug to kill dormant mycobacteria (PMID: 21835980).</td></tr><tr><th>Absorption</th><td>Rapidly and well absorbed from the gastrointestinal tract.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>~10% (bound to plasma proteins)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Pyrazinamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003539" target="_blank">Aldehyde oxidase</a></li></ul></td><td><a href="/metabolites/DBMET00415">5-hydroxypyrazinamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/418">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Approximately 70% of an oral dose is excreted in the urine, mainly by glomerular filtration within 24 hours</td></tr><tr><th>Half life</th><td>9-10 hours (normal conditions)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Side effects include liver injury, arthralgias, anorexia, nausea and vomiting, dysuria,malaise and fever, sideroblastic anemia, adverse effects on the blood clotting mechanism or vascular integrity, and hypersensitivity reactions such as urticaria, pruritis and skin rashes.</td></tr><tr><th>Affected organisms</th><td><ul><li>Mycobacterium tuberculosis</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9813</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9745</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7222</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8219</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9709</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9971</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8985</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8861</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.876</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7754</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8791</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9545</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9731</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9547</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9697</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9353</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9321
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9602
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8145 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9939
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9617
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Dava pharmaceuticals inc</li>
<li>Mikart inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Belgomex Sprl</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li><a href="http://www.versapharm.com">Versapharm Inc.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Pyrazinamide decreases the effect of cyclosporine</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>